

# Protocol for the Examination of Specimens from Patients with Carcinomas of the Larynx

**Protocol applies to all invasive carcinomas of the larynx, including supraglottis, glottis, and subglottis. Mucosal malignant melanoma is included. Lymphomas and sarcomas are not included.**

---

**Based on AJCC/UICC TNM, 7th edition**

Protocol web posting date: October 2009

## **Procedures**

- Biopsy
- Resection

## **Authors**

Lester D. R. Thompson, MD, FCAP\*

Department of Pathology, Southern California Permanente Medical Group, Woodland Hills, CA

Leon Barnes, MD

Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, PA

Diane L. Carlson, MD, FCAP

Department of Pathology, Memorial Sloan-Kettering Cancer Center, New York, NY

John Chan, MD, FCAP

Department of Pathology, Queen Elizabeth Hospital, Hong Kong

Gary Ellis, DDS

ARUP Laboratories, Salt Lake City, UT

Louis B. Harrison, MD

Department of Radiation Oncology, Beth Israel Medical Center, St. Luke's and Roosevelt Hospitals, New York, NY

Jennifer Leigh Hunt, MD, FCAP

Department of Pathology, Massachusetts General Hospital, Boston, MA

Mary S. Richardson, MD, DDS

Department of Pathology, Medical University of South Carolina, Charleston, SC

Jatin Shah, MD, FACS

Head and Neck Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY

Richard Zarbo, MD, DMD, FCAP

Department of Pathology, Henry Ford Health Systems, Detroit, MI

Bruce M. Wenig, MD, FCAP†

Department of Pathology and Laboratory Medicine, Beth Israel Medical Center, St. Luke's and Roosevelt Hospitals, New York, NY

For the Members of the Cancer Committee, College of American Pathologists

\*denotes primary author. † denotes senior author. All other contributing authors are listed alphabetically.

**Previous contributors:** Elizabeth Gillies, MD; John R. Houck Jr, MD; Kyung-Whan Min, MD; David Novis, MD

© 2009 College of American Pathologists (CAP). All rights reserved.

The College does not permit reproduction of any substantial portion of these protocols without its written authorization. The College hereby authorizes use of these protocols by physicians and other health care providers in reporting on surgical specimens, in teaching, and in carrying out medical research for nonprofit purposes. This authorization does not extend to reproduction or other use of any substantial portion of these protocols for commercial purposes without the written consent of the College.

The CAP also authorizes physicians and other health care practitioners to make modified versions of the Protocols solely for their individual use in reporting on surgical specimens for individual patients, teaching, and carrying out medical research for non-profit purposes.

The CAP further authorizes the following uses by physicians and other health care practitioners, in reporting on surgical specimens for individual patients, in teaching, and in carrying out medical research for non-profit purposes: (1) **Dictation** from the original or modified protocols for the purposes of creating a text-based patient record on paper, or in a word processing document; (2) **Copying** from the original or modified protocols into a text-based patient record on paper, or in a word processing document; (3) The use of a **computerized system** for items (1) and (2), provided that the Protocol data is stored intact as a single text-based document, and is not stored as multiple discrete data fields.

Other than uses (1), (2), and (3) above, the CAP does not authorize any use of the Protocols in electronic medical records systems, pathology informatics systems, cancer registry computer systems, computerized databases, mappings between coding works, or any computerized system without a written license from CAP. Applications for such a license should be addressed to the SNOMED Terminology Solutions division of the CAP.

Any public dissemination of the original or modified Protocols is prohibited without a written license from the CAP.

The College of American Pathologists offers these protocols to assist pathologists in providing clinically useful and relevant information when reporting results of surgical specimen examinations of surgical specimens. The College regards the reporting elements in the “Surgical Pathology Cancer Case Summary (Checklist)” portion of the protocols as essential elements of the pathology report. However, the manner in which these elements are reported is at the discretion of each specific pathologist, taking into account clinician preferences, institutional policies, and individual practice.

The College developed these protocols as an educational tool to assist pathologists in the useful reporting of relevant information. It did not issue the protocols for use in litigation, reimbursement, or other contexts. Nevertheless, the College recognizes that the protocols might be used by hospitals, attorneys, payers, and others. Indeed, effective January 1, 2004, the Commission on Cancer of the American College of Surgeons mandated the use of the checklist elements of the protocols as part of its Cancer Program Standards for Approved Cancer Programs. Therefore, it becomes even more important for pathologists to familiarize themselves with these documents. At the same time, the College cautions that use of the protocols other than for their intended educational purpose may involve additional considerations that are beyond the scope of this document.

The inclusion of a product name or service in a CAP publication should not be construed as an endorsement of such product or service, nor is failure to include the name of a product or service to be construed as disapproval.

**Surgical Pathology Cancer Case Summary (Checklist)**

---

Protocol web posting date: October 2009

**LARYNX (SUPRAGLOTTIS, GLOTTIS, SUBGLOTTIS): Incisional Biopsy, Excisional Biopsy, Resection****Select a single response unless otherwise indicated.****Specimen (select all that apply) (Note A)**

- ☐ Larynx, supraglottis
- ☐ Larynx, glottis
- ☐ Larynx, subglottis
- ☐ Other (specify): \_\_\_\_\_
- ☐ Not specified

**Received:**

- ☐ Fresh
- ☐ In formalin
- ☐ Other (specify): \_\_\_\_\_

**Procedure (select all that apply)**

- ☐ Incisional biopsy
- ☐ Excisional biopsy
- ☐ Resection
  - ☐ Stripping (glottis)
  - ☐ Transoral laser excision (glottis)
  - ☐ Supraglottic laryngectomy
  - ☐ Supracricoid laryngectomy
  - ☐ Vertical hemilaryngectomy (specify side): \_\_\_\_\_
  - ☐ Partial laryngectomy (specify type): \_\_\_\_\_
  - ☐ Total laryngectomy
- ☐ Neck (lymph node) dissection (specify): \_\_\_\_\_
- ☐ Other (specify): \_\_\_\_\_
- ☐ Not specified

**\*Specimen Integrity**

- \* ☐ Intact
- \* ☐ Fragmented

**Laryngectomy**

- ☐ Open
- ☐ Unopened

**Specimen Size**

Greatest dimensions: \_\_\_\_ x \_\_\_\_ x \_\_\_\_ cm

\*Additional dimensions (if more than one part): \_\_\_\_ x \_\_\_\_ x \_\_\_\_ cm

\* Data elements with asterisks are not required. However, these elements may be clinically important but are not yet validated or regularly used in patient management.

**Tumor Laterality (select all that apply):**

- ☐ Right
- ☐ Left
- ☐ Bilateral
- ☐ Transglottic:
  - ☐ Yes
  - ☐ No
- ☐ Midline
- ☐ Not specified

**Tumor Site (select all that apply) (Note A)**

- ☐ Larynx, supraglottis
  - ☐ Epiglottis
    - ☐ Lingual aspect
    - ☐ Laryngeal aspect
  - ☐ Aryepiglottic folds
  - ☐ Arytenoid(s)
  - ☐ False vocal cord
  - ☐ Ventricle
- ☐ Larynx, glottis
  - ☐ True vocal cord
  - ☐ Anterior commissure
  - ☐ Posterior commissure
- ☐ Larynx, subglottis
- ☐ Other (specify): \_\_\_\_\_
- ☐ Not specified

**Tumor Focality**

- ☐ Single focus
- ☐ Bilateral
- ☐ Multifocal (specify): \_\_\_\_\_

**Tumor Size**

- Greatest dimension: \_\_\_\_ cm
- \*Additional dimensions: \_\_\_\_ x \_\_\_\_ cm
- ☐ Cannot be determined (see Comment)

**\*Tumor Description (select all that apply)**

- \*Gross subtype:
- \* ☐ Polypoid
  - \* ☐ Exophytic
  - \* ☐ Endophytic
  - \* ☐ Ulcerated
  - \* ☐ Sessile
  - \* ☐ Other (specify): \_\_\_\_\_

**\*Macroscopic Extent of Tumor**

- \*Specify: \_\_\_\_\_

\* Data elements with asterisks are not required. However, these elements may be clinically important but are not yet validated or regularly used in patient management.

**Histologic Type (select all that apply) (Note B)**

☐ Squamous cell carcinoma, conventional

Variants of Squamous Cell Carcinoma

☐ Acantholytic squamous cell carcinoma

☐ Adenosquamous carcinoma

☐ Basaloid squamous cell carcinoma

☐ Papillary squamous cell carcinoma

☐ Spindle cell squamous cell carcinoma

☐ Verrucous carcinoma

☐ Giant cell carcinoma

☐ Lymphoepithelial carcinoma (non-nasopharyngeal)

Neuroendocrine Carcinoma

☐ Typical carcinoid tumor (well differentiated neuroendocrine carcinoma)

☐ Atypical carcinoid tumor (moderately differentiated neuroendocrine carcinoma)

☐ Small cell carcinoma, neuroendocrine type (poorly differentiated neuroendocrine carcinoma)

☐ Combined (or composite) small cell carcinoma, neuroendocrine type

☐ Mucosal malignant melanoma

Carcinomas of Minor Salivary Glands

☐ Adenoid cystic carcinoma

☐ Mucoepidermoid carcinoma

☐ Low grade

☐ Intermediate grade

☐ High grade

☐ Other (specify): \_\_\_\_\_

☐ Other carcinoma (specify): \_\_\_\_\_

☐ Carcinoma, type cannot be determined

**Histologic Grade (Note C)**

☐ Not applicable

☐ GX: Cannot be assessed

☐ G1: Well differentiated

☐ G2: Moderately differentiated

☐ G3: Poorly differentiated

☐ Other (specify): \_\_\_\_\_

**\*Microscopic Tumor Extension**

\*Specify: \_\_\_\_\_

\* Data elements with asterisks are not required. However, these elements may be clinically important but are not yet validated or regularly used in patient management.

**Margins (select all that apply) (Notes D and E)**

- ☐ Cannot be assessed
- ☐ Margins uninvolved by invasive carcinoma  
     Distance from closest margin: \_\_\_\_ mm or \_\_\_\_ cm  
     Specify margin(s), per orientation, if possible: \_\_\_\_\_
- ☐ Margins involved by invasive carcinoma  
     Specify margin(s), per orientation, if possible: \_\_\_\_\_
- ☐ Margins uninvolved by carcinoma in situ (includes moderate and severe dysplasia<sup>#</sup>)  
**(Note D)**  
     Distance from closest margin: \_\_\_\_ mm or \_\_\_\_ cm  
     Specify margin(s), per orientation, if possible: \_\_\_\_\_
- ☐ Margins involved by carcinoma in situ (includes moderate and severe dysplasia<sup>#</sup>)  
**(Note D)**  
     Specify margin(s), per orientation, if possible: \_\_\_\_\_
- ☐ Not applicable

<sup>#</sup>*Applicable only to squamous cell carcinoma and histologic variants.*

**\*Treatment Effect (applicable to carcinomas treated with neoadjuvant therapy)**

- \* ☐ Not identified
- \* ☐ Present (specify): \_\_\_\_\_
- \* ☐ Indeterminate

**Lymph-Vascular Invasion**

- ☐ Not identified
- ☐ Present
- ☐ Indeterminate

**Perineural Invasion (Note F)**

- ☐ Not identified
- ☐ Present
- ☐ Indeterminate

**Lymph Nodes, Extranodal Extension (Note G)**

- ☐ Not identified
- ☐ Present
- ☐ Indeterminate

**Pathologic Staging (pTNM) (Note H)**

*Note: The phrases in italics include clinical findings required for AJCC staging. This clinical information may be unknown to the pathologist. It is included here only for the sake of completeness.*

**TNM Descriptors (required only if applicable) (select all that apply)**

- ☐ m (multiple primary tumors)
- ☐ r (recurrent)
- ☐ y (post-treatment)

\* Data elements with asterisks are not required. However, these elements may be clinically important but are not yet validated or regularly used in patient management.

Primary Tumor (pT)

- \_\_\_ pTX: Cannot be assessed
- \_\_\_ pT0: No evidence of primary tumor
- \_\_\_ pTis: Carcinoma in situ

For All Carcinomas Excluding Mucosal Malignant Melanoma*Primary Tumor (pT): Supraglottis*

- \_\_\_ pT1: Tumor limited to one subsite of supraglottis *with normal vocal cord mobility*
- \_\_\_ pT2: Tumor invades mucosa of more than one adjacent subsite of supraglottis or glottis or region outside the supraglottis (eg, mucosa of base of tongue, vallecula, medial wall of pyriform sinus) *without fixation of the larynx*
- \_\_\_ pT3: Tumor limited to larynx *with vocal cord fixation* and/or invades any of the following: postcricoid area, preepiglottic space, paraglottic space, and/or inner cortex of thyroid cartilage
- \_\_\_ pT4a: Moderately advanced local disease. Tumor invades through the thyroid cartilage and/or invades tissues beyond the larynx (eg, trachea, soft tissues of neck including deep extrinsic muscle of tongue, strap muscles, thyroid, or esophagus)
- \_\_\_ pT4b: Very advanced local disease. Tumor invades prevertebral space, encases carotid artery, or invades mediastinal structures

*Primary Tumor (pT): Glottis*

- \_\_\_ pT1: Tumor limited to the vocal cord(s) (may involve anterior or posterior commissure) *with normal mobility*
- \_\_\_ pT1a: Tumor limited to one vocal cord
- \_\_\_ pT1b: Tumor involves both vocal cords
- \_\_\_ pT2: Tumor extends to supraglottis and/or subglottis *and/or with impaired vocal cord mobility*
- \_\_\_ pT3: Tumor limited to the larynx *with vocal cord fixation* and/or invades paraglottic space and/or minor thyroid cartilage erosion (eg, inner cortex) (**Note H**)
- \_\_\_ pT4a: Moderately advanced local disease. Tumor invades through the outer cortex of the thyroid cartilage and/or invades tissues beyond the larynx (eg, trachea, soft tissues of neck including deep extrinsic muscle of the tongue, strap muscles, thyroid, or esophagus) (**Note H**)
- \_\_\_ pT4b: Very advanced local disease. Tumor invades prevertebral space, encases carotid artery, or invades mediastinal structures

*Primary Tumor (pT): Subglottis*

- \_\_\_ pT1: Tumor limited to subglottis
- \_\_\_ pT2: Tumor extends to vocal cord(s) *with normal or impaired mobility*
- \_\_\_ pT3: Tumor limited to larynx *with vocal cord fixation*
- \_\_\_ pT4a: Moderately advanced local disease. Tumor invades cricoid or thyroid cartilage and/or invades tissues beyond the larynx (eg, trachea, soft tissues of neck including deep extrinsic muscles of the tongue, strap muscles, thyroid, or esophagus)
- \_\_\_ pT4b: Very advanced local disease. Tumor invades prevertebral space, encases carotid artery, or invades mediastinal structures

\* Data elements with asterisks are not required. However, these elements may be clinically important but are not yet validated or regularly used in patient management.

*Regional Lymph Nodes (pN)<sup>#</sup> (Notes I through L)*

- \_\_\_ pNX: Cannot be assessed
- \_\_\_ pN0: No regional lymph node metastasis
- \_\_\_ pN1: Metastasis in a single ipsilateral lymph node, 3 cm or less in greatest dimension
- \_\_\_ pN2: Metastasis in a single ipsilateral lymph node, more than 3 cm but not more than 6 cm in greatest dimension, or in multiple ipsilateral lymph nodes, none more than 6 cm in greatest dimension, or in bilateral or contralateral lymph nodes, none more than 6 cm in greatest dimension
- \_\_\_ pN2a: Metastasis in a single ipsilateral lymph node, more than 3 cm but not more than 6 cm in greatest dimension
- \_\_\_ pN2b: Metastasis in multiple ipsilateral lymph nodes, none more than 6 cm in greatest dimension
- \_\_\_ pN2c: Metastasis in bilateral or contralateral lymph nodes, none more than 6 cm in greatest dimension
- \_\_\_ pN3: Metastasis in a lymph node more than 6 cm in greatest dimension

Specify: Number examined: \_\_\_  
 Number involved: \_\_\_

\*Size (greatest dimension) of the largest positive lymph node: \_\_\_ **(Note K)**

<sup>#</sup>*Superior mediastinal lymph nodes are considered regional lymph nodes (level VII).  
 Midline nodes are considered ipsilateral nodes.*

*Distant Metastasis (pM)*

- \_\_\_ Not applicable
- \_\_\_ pM1: Distant metastasis
- \*Specify site(s), if known: \_\_\_\_\_
- \* Source of pathologic metastatic specimen (specify): \_\_\_\_\_

For Mucosal Malignant Melanoma*Primary Tumor (pT)*

- \_\_\_ pT3: Mucosal disease
- \_\_\_ pT4a: Moderately advanced disease. Tumor involving deep soft tissue, cartilage, bone, or overlying skin
- \_\_\_ pT4b: Very advanced disease. Tumor involving brain, dura, skull base, lower cranial nerves (IX, X, XI, XII), masticator space, carotid artery, prevertebral space, or mediastinal structures

*Regional Lymph Nodes (pN)*

- \_\_\_ pNX: Regional lymph nodes cannot be assessed
- \_\_\_ pN0: No regional lymph node metastases
- \_\_\_ pN1: Regional lymph node metastases present

*Distant Metastasis (pM)*

- \_\_\_ Not applicable
- \_\_\_ pM1: Distant metastasis present
- \*Specify site(s), if known: \_\_\_\_\_
- \* Source of pathologic metastatic specimen (specify): \_\_\_\_\_

\* Data elements with asterisks are not required. However, these elements may be clinically important but are not yet validated or regularly used in patient management.



**\*Additional Pathologic Findings (select all that apply)**

- \* ☐ None identified
- \* ☐ Keratinizing dysplasia **(Note M)**
  - \* ☐ Mild
  - \* ☐ Moderate
  - \* ☐ Severe (carcinoma in situ)
- \* ☐ Non-keratinizing dysplasia **(Note M)**
  - \* ☐ Mild
  - \* ☐ Moderate
  - \* ☐ Severe (carcinoma in situ)
- \* ☐ Inflammation (specify type): \_\_\_\_\_
- \* ☐ Squamous metaplasia
- \* ☐ Epithelial hyperplasia
- \* ☐ Colonization
  - \* ☐ Fungal
  - \* ☐ Bacterial
- \* ☐ Other (specify): \_\_\_\_\_

**\*Ancillary Studies (Note N)**

- \* Specify type(s): \_\_\_\_\_
- \* Specify result(s): \_\_\_\_\_

**\*Clinical History (select all that apply)**

- \* ☐ Neoadjuvant therapy
  - \* ☐ Yes (specify type): \_\_\_\_\_
  - \* ☐ No
  - \* ☐ Indeterminate
- \* ☐ Other (specify): \_\_\_\_\_

**\*Comment(s)**

\* Data elements with asterisks are not required. However, these elements may be clinically important but are not yet validated or regularly used in patient management.

## Explanatory Notes

---

### Scope of Guidelines

The reporting of oral cancer including the lip is facilitated by the provision of a checklist illustrating the features required for comprehensive patient care. However, there are many cases in which the individual practicalities of applying such a checklist may not be straightforward. Common examples include finding the prescribed number of lymph nodes, trying to determine the levels of the radical neck dissection, and determining if isolated tumor cells in a lymph node represent metastatic disease. Checklists have evolved to include clinical, radiographic, morphologic, immunohistochemical, and molecular results in an effort to guide clinical management. Adjuvant and neoadjuvant therapy can significantly alter histologic findings, making accurate classification an increasingly complex and demanding task. This checklist tries to remain simple while still incorporating important pathologic features as proposed by the American Joint Committee on Cancer (AJCC) cancer staging manual, the World Health Organization classification of tumours, the TNM classification, the American College of Surgeons Commission on Cancer, and the International Union on Cancer (UICC). This checklist is to be used as a guide and resource, an adjunct to diagnosing and managing cancers of the oral cavity in a standardized manner. It should not be used as a substitute for dissection or grossing techniques and does not give histologic parameters to reach the diagnosis. Subjectivity is always a factor, and elements listed are not meant to be arbitrary but are meant to provide uniformity of reporting across all the disciplines that use the information. It is a foundation of practical information that will help to meet the requirements of daily practice to benefit both clinicians and patients alike.

### A. Anatomical Sites and Subsites for the Larynx (Figure 1)

#### Supraglottis

- Epilarynx, including marginal zone
  - Suprahyoid epiglottis, including tip, lingual (anterior) and laryngeal surfaces
  - Aryepiglottic fold, laryngeal aspect
  - Arytenoid
- Supraglottis, excluding epilarynx
  - Infrahyoid epiglottis
  - Ventricular bands (false cords)
  - Ventricle

#### Glottis

- Vocal cords
- Anterior commissure
- Posterior commissure


#### Subglottis

The protocol applies to all carcinomas arising at these sites.<sup>1</sup> The piriform sinus represents part of the hypopharynx which expands bilaterally and forward around the sides of the larynx and lies between the larynx and the thyroid cartilage. Cancers of the piriform sinus are included in the protocol on pharynx cancers.


**Anatomic Compartments (Figure 1)**

The anatomic compartments of the larynx include:


1. Supraglottic larynx extending from the tip of the epiglottis to a horizontal line passing through the apex of the ventricle; structures included in this compartment are the epiglottis (lingual and laryngeal aspects), aryepiglottic folds, arytenoids, false vocal cords and the ventricle.
2. Glottic region, which extends from the ventricle to approximately 0.5 to 1.0 cm below the free level of the true vocal cord and includes the anterior and posterior commissures and the true vocal cord.
3. Subglottic larynx, which extends approximately 1.0 cm below the level of the true vocal cord to the inferior rim of the cricoid cartilage.
4. The paraglottic space is a potential space deep to the ventricles and saccules filled with adipose tissue and connective tissue (Figure 2). It is bounded by the conus elasticus inferiorly, the thyroid cartilage laterally, the quadrangular membrane medially, and the piriform sinus posteriorly.<sup>2</sup> Like the paraglottic space, the pre-epiglottic space is filled with adipose tissue and connective tissue (Figure 3); it is triangular in shape and is bounded by the thyroid cartilage and thyrohyoid membrane anteriorly, the epiglottis and thyroepiglottic ligament posteriorly, and the hyoepiglottic ligament at its base (Figures 1 and 2).<sup>2</sup> The paraglottic and preglottic spaces contain lymphatics and blood vessels but no lymph nodes.<sup>2</sup>



**Figure 1.** Anatomic compartments of the larynx. From Cocke EW Jr, Wang CC. Part I - Cancer of the larynx: selecting optimum treatment. *CA Cancer J Clin.* 1976;26:194-200. Figure by J.H. Ogura, MD.



**Figure 2.** The paraglottic space. From *World Health Organization Classification of Tumours: Pathology and Genetics of Head and Neck Tumours*. Lyon, France: IARC Press; 2005. Reprinted with permission.



**Figure 3.** The pre-epiglottic space. From *World Health Organization Classification of Tumours: Pathology and Genetics of Head and Neck Tumours*. Lyon, France: IARC Press; 2005. Reprinted with permission.

### Site-Specific Carcinomas

1. Supraglottic squamous cell carcinoma represents a squamous cell carcinoma that involves the structures of the supraglottic larynx, including the epiglottis (laryngeal and lingual surfaces), aryepiglottic folds, arytenoids, false vocal cords and ventricles.
2. Glottic squamous cell carcinoma represents a squamous cell carcinoma that involves the structures of the glottis, including the true vocal cords, and the anterior and posterior commissures.
3. Subglottic squamous cell carcinoma represents a squamous cell carcinoma that involves the subglottis which begins 1 cm below the apex of the ventricle to its inferior border represented by the rim of the cricoid cartilage.
4. Transglottic carcinomas represent a carcinoma that crosses the ventricles in a vertical direction arising in either the glottic or supraglottic larynx

### B. Histological Type

A modification of the World Health Organization (WHO) classification of carcinomas of the larynx is shown below.<sup>3</sup> This list may not be complete. This protocol applies to carcinomas and melanomas and does not apply to lymphomas or sarcomas.

#### Carcinomas of Larynx

Squamous cell carcinoma (conventional)

Squamous cell carcinoma, variant (in alphabetical order)

- Acantholytic squamous cell carcinoma
- Adenosquamous carcinoma
- Basaloid squamous cell carcinoma
- Papillary squamous cell carcinoma
- Spindle cell squamous carcinoma
- Verrucous carcinoma

Giant cell carcinoma

Lymphoepithelial carcinoma

Neuroendocrine carcinoma

- Typical carcinoid tumor (well differentiated neuroendocrine carcinoma)
- Atypical carcinoid tumor (moderately differentiated neuroendocrine carcinoma)
- Small cell carcinoma, neuroendocrine type (poorly differentiated neuroendocrine carcinoma)
- Combined (or composite) small cell carcinoma, neuroendocrine type<sup>#</sup>

<sup>#</sup> Represents a carcinoma showing combined features of small cell neuroendocrine carcinoma associated with a squamous or adenocarcinomatous component.<sup>4</sup>

Mucosal malignant melanoma

#### Carcinomas of Minor Salivary Glands

Adenoid cystic carcinoma

Mucoepidermoid carcinoma

Other (specify type)

### C. Histologic Grade

For histologic types of carcinomas that are amenable to grading, 3 histologic grades are suggested, as shown below. When a tumor manifests more than one grade of differentiation, the surgical report must designate both the highest and the most prevalent tumor grades.<sup>5,6</sup>

Grade X	Cannot be assessed
Grade 1	Well differentiated
Grade 2	Moderately differentiated
Grade 3	Poorly differentiated

This grading system does not apply to all salivary gland tumors. The histologic (microscopic) grading of salivary gland carcinomas has been shown to be an independent predictor of behavior and plays a role in optimizing therapy.<sup>7-11</sup> Further, there is often a positive correlation between histologic grade and clinical stage. With some exceptions, histologic grading is predicated on cytomorphic features. In this histologic grading scheme, 3 histologic grades are suggested, as follows:

Grade 1	Well differentiated = Low-grade
Grade 2	Moderately differentiated = Intermediate-grade
Grade 3	Poorly differentiated = High-grade
Grade X	Cannot be assessed

When a tumor manifests more than 1 grade of differentiation, the surgical report must designate both the highest and the most prevalent tumor grades. In some carcinomas, histologic grading may be based on growth pattern, such as in adenoid cystic carcinoma, for which a histologic high-grade variant has been recognized based on the percentage of solid growth.<sup>7</sup> Those adenoid cystic carcinomas showing 30% or greater of solid growth pattern are considered to be histologically high-grade carcinomas.<sup>7,9,12</sup> The histologic grading of mucoepidermoid carcinoma includes a combination of growth pattern characteristics (eg, cystic, solid, neurotropism) and cytomorphic findings (eg, anaplasia, mitoses, necrosis).<sup>13-15</sup>

### D. Surgical Margins

Reporting of surgical margins should include information regarding the distance of invasive carcinoma, carcinoma in situ, or high-grade dysplasia (moderate to severe) from the surgical margin. Closeness of the above, microscopically less than 5 mm, from the surgical border should be noted in the report. Presence of the above lesions found within 5 mm of the surgical border carry a significant risk for subsequent local recurrence.<sup>16-18</sup> The ability to control surgical margins by transoral laser excision is, at best, uncertain. By the nature of the excised tissues precluding orientation and margin designation/identification, there is no need for the pathology report to include the margin status in laser excised specimens. Reporting of surgical margins for carcinomas of the minor salivary glands should follow those used for squamous cell carcinoma of oral cavity.

### Keratinizing Dysplasia

The types of intraepithelial dysplasia of the upper aerodigestive tract (UADT) include nonkeratinizing ("classic") dysplasia and keratinizing dysplasia. Of the two types of dysplasias, the keratinizing dysplasias are significantly more common than the

nonkeratinizing dysplasias. For both types of UADT intraepithelial dysplasias, grading includes mild, moderate, and severe forms, with the latter category being synonymous with carcinoma in situ. It must be noted that in the setting of keratinizing dysplasia, full thickness dysplasia of the surface epithelium, representing the histologic definition for carcinoma in situ, is an uncommon occurrence. Nevertheless, there are keratinizing dysplasias that lack full thickness dysplasia and yet carry a significant risk to invasive carcinoma.<sup>19</sup> Due to the fact that invasive carcinoma develops from keratinizing dysplasia in which there is an absence of full thickness dysplasia, the grading of UADT dysplasias is problematic and lacks reproducibility among pathologists (see below under Note M). Since there is no significant statistical difference in the risk to invasive carcinoma between the category of keratinizing moderate dysplasia and keratinizing severe dysplasia,<sup>19</sup> the suggestion has been entertained of adopting a Bethesda-like classification to keratinizing dysplasias of the UADT, including a low-grade category limited to keratinizing mild dysplasia and a high-grade category to include keratinizing moderate and severe dysplasias.<sup>20</sup> As such, it must be recognized that keratinizing severe dysplasia, even if not “full thickness,” should for all intents and purposes be dealt with in a similar manner as classically defined carcinoma in situ so that in evaluating surgical margins for the presence or absence of dysplasia/carcinoma in situ, keratinizing moderate and severe dysplasias should be viewed as a single category relative to risk of progression to invasive carcinoma. Such a risk does not include keratinizing mild dysplasia. In summary, the presence of keratinizing mild dysplasia at (or near) a surgical margin should not be viewed/reported as a positive margin, whereas the presence of keratinizing moderate or severe dysplasia at (or near) a surgical margin should be viewed/reported as a positive margin.

#### **E. Orientation of Specimen**

Complex specimens should be examined and oriented with the assistance of attending surgeons. Direct communication between the surgeon and pathologist is a critical component in specimen orientation and proper sectioning. Whenever possible, the tissue examination request form should include a drawing of the resected specimen showing the extent of the tumor and its relation to the anatomic structures of the region. The lines and extent of the resection can be depicted on preprinted adhesive labels and attached to the surgical pathology request forms.

#### **F. Perineural Invasion**

The presence of perineural invasion (neurotropism) is an important predictor of poor prognosis in head and neck cancer of virtually all sites.<sup>21</sup> The presence of perineural invasion (neurotropism) in the primary cancer is associated with poor local disease control and regional control, as well as being associated with metastasis to regional lymph nodes.<sup>21</sup> Further, perineural invasion is associated with decrease in disease-specific survival and overall survival.<sup>21</sup> There is conflicting data relative to an association between the presence of perineural invasion and the development of distant metastasis, with some studies showing an increased association with distant metastasis, but other studies not showing any correlation with distant metastasis.<sup>21</sup> The relationship between perineural invasion and prognosis is independent of nerve diameter.<sup>22</sup> Although perineural invasion of small unnamed nerves may not produce clinical symptoms, the reporting of perineural invasion includes nerves of all sizes including small peripheral nerves (ie, less than 1 mm in diameter). Aside from the impact on prognosis, the presence of perineural invasion also guides therapy. Concurrent adjuvant chemoradiation therapy has been shown to improve outcomes in patients with perineural invasion (as well as in patients with extranodal extension and bone invasion).<sup>23,24</sup> Given

the significance relative to prognosis and treatment, perineural invasion is a required data element in the reporting of head and neck cancers.

### G. Extranodal Extension

The status of cervical lymph nodes is the single most important prognostic factor in aerodigestive cancer. All macroscopically negative or equivocal lymph nodes should be submitted in toto. Grossly positive nodes may be partially submitted for microscopic documentation of metastasis. Reporting of lymph nodes containing metastasis should include whether there is presence or absence of extra-nodal extension (EE). This finding consists of extension of metastatic tumor, present within the confines of the lymph node, through the lymph node capsule into the surrounding connective tissue, with or without associated stromal reaction. If macroscopic examination suggests EE, this tissue should be submitted for microscopic confirmation. EE is a predictor of regional relapse and a criterion for postoperative radiotherapy.<sup>25-28</sup>

### H. TNM and Stage Groupings

The protocol recommends the TNM staging system of the American Joint Committee on Cancer (AJCC) and the International Union Against Cancer (UICC) for larynx cancer.<sup>1,29</sup> Of note in the 7<sup>th</sup> edition of the AJCC staging of head and neck cancers<sup>1</sup> is the division of T4 lesions into T4a (moderately advanced local disease) and T4b (very advanced local disease), leading to the stratification of stage IV into stage IVA (moderately advanced local/regional disease), stage IVB (very advanced local/regional disease), and stage IVC (distant metastatic disease). Relative to supraglottic and glottic cancers, the determination between a T3 cancer with “minor thyroid cartilage erosion” versus a T4a cancer with “invasion through thyroid cartilage” can be problematic as there is no specific definition whether “invasion through thyroid cartilage” means complete infiltration through and through the cartilage or whether tumors invading short of completely through the thyroid cartilage (eg, half way through, other) qualify as a pT4a cancer. When confronted with this issue, review of the operative report and imaging studies, as well as direct communication with the surgeon may provide insight or consensus of opinion. Generally, if the tumor invades at least into the center of the cartilage but not “through,” most authorities would stage such a lesion as a T4a cancer.

The 7<sup>th</sup> edition of the AJCC staging of head and neck cancers includes mucosal malignant melanomas.<sup>1</sup> Approximately two-thirds of mucosal malignant melanomas arise in the sinonasal tract, one-quarter are found in the oral cavity, and the remainder occur only sporadically in other mucosal sites of the head and neck.<sup>1</sup> Even small cancers behave aggressively with high rates of recurrence and death.<sup>1</sup> To reflect this aggressive behavior, primary cancers limited to the mucosa are considered T3 lesions. Advanced mucosal melanomas are classified as T4a and T4b. The anatomic extent criteria to define *moderately advanced* (T4a) and *very advanced* (T4b) disease are given below. The AJCC staging for mucosal malignant melanomas does not provide for the histologic definition of a T3 lesion; as the majority of mucosal malignant melanomas are invasive at presentation, mucosal based melanomas (T3 lesions) include those lesions that involve either the epithelium and/or lamina propria of the involved site. Rare examples of *in situ* mucosal melanomas occur, but *in situ* mucosal melanomas are excluded from staging, as they are extremely rare.<sup>1</sup>



**For All Carcinomas Excluding Mucosal Malignant Melanoma**Primary Tumor: Supraglottis

TX	Cannot be assessed
T0	No evidence of primary tumor
Tis	Carcinoma in situ
T1	Tumor limited to one subsite of supraglottis <i>with normal vocal cord mobility</i>
T2	Tumor invades mucosa of more than one adjacent subsite of supraglottis or glottis or region outside the supraglottis (eg, mucosa of base of tongue, vallecula, medial wall of pyriform sinus) <i>without fixation of the larynx</i>
T3	Tumor limited to larynx <i>with vocal cord fixation</i> and/or invades any of the following: postcricoid area, pre-epiglottic space, paraglottic space, and/or minor thyroid cartilage erosion (eg, inner cortex)
T4a	Moderately advanced local disease. Tumor invades through the thyroid cartilage and/or invades tissues beyond the larynx (eg, trachea, soft tissues of neck including deep extrinsic muscle of tongue, strap muscles, thyroid, or esophagus)
T4b	Very advanced local disease. Tumor invades prevertebral space, encases carotid artery, or invades mediastinal structures

Primary Tumor: Glottis

TX	Cannot be assessed
T0	No evidence of primary tumor
Tis	Carcinoma in situ
T1	Tumor limited to the vocal cord(s) (may involve anterior or posterior commissure) <i>with normal mobility</i>
T1a	Tumor limited to one vocal cord
T1b	Tumor involves both vocal cords
T2	Tumor extends to supraglottis and/or subglottis <i>and/or with impaired vocal cord mobility</i>
T3	Tumor limited to the larynx <i>with vocal cord fixation</i> and/or invasion of paraglottic space, and/or inner cortex of thyroid cartilage
T4a	Tumor invades through the outer cortex of the thyroid cartilage and/or invades tissues beyond the larynx (eg, trachea, soft tissues of neck including deep extrinsic muscle of the tongue, strap muscles, thyroid, or esophagus)
T4b	Tumor invades prevertebral space, encases carotid artery, or invades mediastinal structures

Primary Tumor: Subglottis

TX	Cannot be assessed
T0	No evidence of primary tumor
Tis	Carcinoma in situ
T1	Tumor limited to subglottis
T2	Tumor extends to vocal cord(s) <i>with normal or impaired mobility</i>
T3	Tumor limited to larynx <i>with vocal cord fixation</i>
T4a	Tumor invades cricoid or thyroid cartilage and/or invades tissues beyond the larynx (eg, trachea, soft tissues of neck including deep extrinsic muscles of the tongue, strap muscles, thyroid, or esophagus)
T4b	Tumor invades prevertebral space, encases carotid artery, or invades mediastinal structures

Regional Lymph Nodes<sup>#</sup>

NX	Cannot be assessed
N0	No regional lymph node metastasis
N1	Metastasis in a single ipsilateral lymph node, 3 cm or less in greatest dimension
N2	Metastasis in a single ipsilateral lymph node, more than 3 cm but not more than 6 cm in greatest dimension, or in multiple ipsilateral lymph nodes, none more than 6 cm in greatest dimension, or in bilateral or contralateral lymph nodes, none more than 6 cm in greatest dimension
N2a	Metastasis in a single ipsilateral lymph node, more than 3 cm but not more than 6 cm in greatest dimension
N2b	Metastasis in multiple ipsilateral lymph nodes, none more than 6 cm in greatest dimension
N2c	Metastasis in bilateral or contralateral lymph nodes, none more than 6 cm in greatest dimension
N3	Metastasis in a lymph node more than 6 cm in greatest dimension

<sup>#</sup> Superior mediastinal lymph nodes are considered regional lymph nodes (level VII).  
Midline nodes are considered ipsilateral nodes.

Distant Metastasis

M0	No distant metastasis
M1	Distant metastasis

**For Mucosal Malignant Melanoma**Primary Tumor

T3	Mucosal disease
T4a	Moderately advanced disease. Tumor involving deep soft tissue, cartilage, bone, or overlying skin
T4b	Very advanced disease. Tumor involving brain, dura, skull base, lower cranial nerves (IX, X, XI, XII), masticator space, carotid artery, prevertebral space, or mediastinal structures

Regional Lymph Nodes

NX	Regional lymph nodes cannot be assessed
N0	No regional lymph node metastases
N1	Regional lymph node metastases present

Distant Metastasis

M0	No distant metastasis
M1	Distant metastasis present

By AJCC/UICC convention, the designation “T” refers to a primary tumor that has not been previously treated. The symbol “p” refers to the pathologic classification of the TNM, as opposed to the clinical classification, and is based on gross and microscopic examination. pT entails a resection of the primary tumor or biopsy adequate to evaluate the highest pT category, pN entails removal of nodes adequate to validate lymph node metastasis, and pM implies microscopic examination of distant lesions. Clinical classification (cTNM) is usually carried out by the referring physician before treatment during initial evaluation of the patient or when pathologic classification is not possible.

Pathologic staging is usually performed after surgical resection of the primary tumor. Pathologic staging depends on pathologic documentation of the anatomic extent of disease, whether or not the primary tumor has been completely removed. If a biopsied tumor is not resected for any reason (eg, when technically unfeasible) and if the highest T and N categories or the M1 category of the tumor can be confirmed microscopically, the criteria for pathologic classification and staging have been satisfied without total removal of the primary cancer.

### T Category Considerations

Supraglottis. Normal vocal cord mobility (T1), fixation of the larynx (T2), and vocal cord fixation (T3) may only be determined clinically.

Glottis. Normal vocal cord mobility (T1), impaired vocal cord mobility (T2), and vocal cord fixation (T3) may only be determined clinically.

Subglottis. Normal or impaired vocal cord mobility (T2) and vocal cord fixation (T3) may only be determined clinically.

### Stage Groupings: Supraglottis, Glottis, and Subglottis - For All Cancers Except Mucosal Malignant Melanoma

Stage 0	Tis	N0	M0
Stage I	T1	N0	M0
Stage II	T2	N0	M0
Stage III	T1	N1	M0
	T2	N1	M0
	T3	N0,N1	M0
Stage IVA	T1,T2,T3	N2	M0
	T4a	N0,N1,N2	M0
Stage IVB	T4b	Any N	M0
	Any T	N3	M0
Stage IVC	Any T	Any N	M1

### Stage Groupings – For Mucosal Malignant Melanoma

Stage III	T3	N0	M0
Stage IVA	T4a	N0	M0
	T3-T4a	N1	M0
Stage IVB	T4b	Any N	M0
Stage IVC	Any T	Any N	M1

### TNM Descriptors

For identification of special cases of TNM or pTNM classifications, the “m” suffix and “y” and “r” prefixes are used. Although they do not affect the stage grouping, they indicate cases needing separate analysis.

The “m” suffix indicates the presence of multiple primary tumors in a single site and is recorded in parentheses: pT(m)NM.

The “y” prefix indicates those cases in which classification is performed during or following initial multimodality therapy (ie, neoadjuvant chemotherapy, radiation therapy,

or both chemotherapy and radiation therapy). The cTNM or pTNM category is identified by a “y” prefix. The ycTNM or ypTNM categorizes the extent of tumor actually present at the time of that examination. The “y” categorization is not an estimate of tumor prior to multimodality therapy (ie, before initiation of neoadjuvant therapy).

The “r” prefix indicates a recurrent tumor when staged after a documented disease-free interval, and is identified by the “r” prefix: rTNM.

### Additional Descriptors

#### Residual Tumor (R)

Tumor remaining in a patient after therapy with curative intent (eg, surgical resection for cure) is categorized by a system known as R classification, shown below.

RX	Presence of residual tumor cannot be assessed
R0	No residual tumor
R1	Microscopic residual tumor
R2	Macroscopic residual tumor

For the surgeon, the R classification may be useful to indicate the known or assumed status of the completeness of a surgical excision. For the pathologist, the R classification is relevant to the status of the margins of a surgical resection specimen. That is, tumor involving the resection margin on pathologic examination may be assumed to correspond to residual tumor in the patient and may be classified as macroscopic or microscopic according to the findings at the specimen margin(s).

#### **I. Classification of Neck Dissection**

1. Radical neck dissection
2. Modified radical neck dissection, internal jugular vein and/or sternocleidomastoid muscle spared
3. Selective neck dissection (SND), as specified by the surgeon
  - a. Supraomohyoid neck dissection
  - b. Posterolateral neck dissection
  - c. Lateral neck dissection
  - d. Central compartment neck dissection
4. Selective neck dissection (SND), as specified by the surgeon -“SND” with levels and sublevels designated (**Figure 4**)<sup>30-32</sup>
5. Extended radical neck dissection, as specified by the surgeon

#### **J. Regional Lymph Nodes (pN0): Isolated Tumor Cells**

Isolated tumor cells (ITCs) are single cells or small clusters of cells not more than 0.2 mm in greatest dimension. Lymph nodes or distant sites with ITCs found by either histologic examination, immunohistochemistry, or non-morphologic techniques (eg, flow cytometry, DNA analysis, polymerase chain reaction [PCR] amplification of a specific tumor marker) should be classified as N0 or M0, respectively. Specific denotation of the assigned N category is suggested as follows for cases in which ITCs are the only evidence of possible metastatic disease.<sup>29,33,34</sup>

pN0	No regional lymph node metastasis histologically, no examination for isolated tumor cells (ITCs)
pN0(i-)	No regional lymph node metastasis histologically, negative morphologic (any morphologic technique, including hematoxylin-eosin and immunohistochemistry) findings for ITCs
pN0(i+)	No regional lymph node metastasis histologically, positive morphologic (any morphologic technique, including hematoxylin-eosin and immunohistochemistry) findings for ITCs
pN0(mol-)	No regional lymph node metastasis histologically, negative non-morphologic (molecular) findings for ITCs
pN0(mol+)	No regional lymph node metastasis histologically, positive non-morphologic (molecular) findings for ITCs

For purposes of pathologic evaluation, lymph nodes are organized by levels as shown in Figure 4.<sup>35</sup>



**Figure 4.** The six sublevels of the neck for describing the location of lymph nodes within levels I, II, and V. Level IA, submental group; level IB, submandibular group; level IIA, upper jugular nodes along the carotid sheath, including the subdigastric group; level IIB, upper jugular nodes in the submuscular recess; level VA, spinal accessory nodes; and level VB, the supraclavicular and transverse cervical nodes. From: Flint PW, et al, eds. *Cummings Otolaryngology: Head and Neck Surgery*. 5th ed. Philadelphia, PA; Saunders: 2010. Reproduced with permission © Elsevier.

In order for pathologists to properly identify these nodes, they must be familiar with the terminology of the regional lymph node groups and with the relationships of those groups to the regional anatomy. Which lymph node groups surgeons submit for histopathologic evaluation depends on the type of neck dissection they perform. Therefore, surgeons must supply information on the types of neck dissections that they perform and the details of the local anatomy in the specimens they submit for examination or, in other manners, orient those specimens for pathologists.

If it is not possible to assess the levels of lymph nodes (for instance, when the anatomic landmarks in the excised specimens are not specified), then the lymph node levels may be estimated as follows: level II, upper third of internal jugular (IJ) vein or neck

specimen; level III, middle third of IJ vein or neck specimen; level IV, lower third of IJ vein or neck specimen, all anterior to the sternocleidomastoid muscle.

**Level I. Submental Group (Sublevel IA)**

Lymph nodes within the triangular boundary of the anterior belly of the digastric muscles and the hyoid bone.

**Level I. Submandibular Group (Sublevel IB)**

Lymph nodes within the boundaries of the anterior and posterior bellies of the digastric muscle and the body of the mandible. The submandibular gland is included in the specimen when the lymph nodes within this triangle are removed.

**Level II. Upper Jugular Group (Sublevels IIA and IIB)**

Lymph nodes located around the upper third of the internal jugular vein and adjacent spinal accessory nerve extending from the level of the carotid bifurcation (surgical landmark) or hyoid bone (clinical landmark) to the skull base. The posterior boundary is the posterior border of the sternocleidomastoid muscle, and the anterior boundary is the lateral border of the sternohyoid muscle.

**Level III. Middle Jugular Group**

Lymph nodes located around the middle third of the internal jugular vein extending from the carotid bifurcation superiorly to the omohyoid muscle (surgical landmark), or cricothyroid notch (clinical landmark) inferiorly. The posterior boundary is the posterior border of the sternocleidomastoid muscle, and the anterior boundary is the lateral border of the sternohyoid muscle.

**Level IV. Lower Jugular Group**

Lymph nodes located around the lower third of the internal jugular vein extending from the omohyoid muscle superiorly to the clavicle inferiorly. The posterior boundary is the posterior border of the sternocleidomastoid muscle, and the anterior boundary is the lateral border of the sternohyoid muscle.

**Level V. Posterior Triangle Group (Sublevels VA and VB)**

This group comprises predominantly the lymph nodes located along the lower half of the spinal accessory nerve and the transverse cervical artery. The supraclavicular nodes are also included in this group. The posterior boundary of the posterior triangle is the anterior border of the trapezius muscle, the anterior boundary of the posterior triangle is the posterior border of the sternocleidomastoid muscle, and the inferior boundary of the posterior triangle is the clavicle.

**Level VI. Anterior (Central) Compartment**

Lymph nodes in this compartment include the pre- and paratracheal nodes, precricoid (Delphian) node, and the perithyroidal nodes, including the lymph nodes along the recurrent laryngeal nerve. The superior boundary is the hyoid bone, the inferior boundary is the suprasternal notch, the lateral boundaries are the common carotid arteries, and the posterior boundary by the prevertebral fascia.

**Level VII. Superior Mediastinal Lymph Nodes**

Metastases at level VII are considered regional lymph node metastases; all other mediastinal lymph node metastases are considered distant metastases.

Lymph node groups removed from areas not included in the above levels, eg, scalene, suboccipital, and retropharyngeal, should be identified and reported from all levels separately. Midline nodes are considered ipsilateral nodes.

## **K. Lymph Nodes**

### **Lymph Node Number**

Histological examination of a selective neck dissection specimen will ordinarily include 6 or more lymph nodes. Histological examination of a radical or modified radical neck dissection specimen will ordinarily include 10 or more lymph nodes in the untreated neck.

### **Measurement of Tumor Metastasis**

The cross-sectional diameter of the largest metastasis in a lymph node containing metastatic tumor is measured in the gross specimen at the time of macroscopic examination or, if necessary, on the histologic slide at the time of microscopic examination. There is conflicting data in the literature on the significance of the size of the largest metastatic lymph node on the risk of regional recurrence and a predictor of poor overall survival.<sup>21</sup> While the diameter of the largest positive lymph node may potentially serve as a predictor of outcome, it may not represent an independent predictor of outcome when other pathologic factors are considered.<sup>21</sup>

## **L. Special Procedures for Lymph Nodes**

The risk of regional (cervical neck) nodal spread from cancers of the pharynx is high.<sup>1</sup> At the current time, no additional special techniques are required other than routine histology for the assessment of nodal metastases. Immunohistochemistry and PCR to detect isolated tumor cells are considered investigational techniques at this time.

## **M. Dysplasia of the Upper Aerodigestive Tract (UADT)**

In contrast to the uterine cervix in which the nonkeratinizing ("classic") form of epithelial dysplasia is most common resulting in a reproducible and clinically useful grading scheme of mild, moderate, and severe dysplasia (ie, carcinoma in situ), the majority of the UADT mucosal lesions fall under the designation of keratinizing dysplasias. The criteria for evaluating keratinizing dysplasias are less well defined, and the diagnosis of severe keratinizing (intraepithelial) dysplasia remains controversial. In particular, the definition of severe dysplasia in the setting of keratosis is broader than the highly reproducible pattern seen in the uterine cervix and includes a microscopically heterogeneous group of lesions. In the setting of keratinizing dysplasia where surface maturation is retained with only partial replacement of the epithelium by atypical cells, severe dysplasia includes those lesions in which the epithelial alterations are so severe that there would be a high probability for the progression to an invasive carcinoma if left untreated. The evaluation of keratinizing dysplasia includes cellular abnormalities (ie, cytomorphology) and maturation abnormalities (ie, architectural alterations). At present, the preferred grading for keratinizing dysplasias of the UADT include mild, moderate, and severe dysplasia, depending on the degree and extent of cellular and maturation alterations that are present.<sup>36</sup> Using the definition of carcinoma in situ (CIS) as applied to the uterine cervix requires loss of maturation of squamous epithelium; therefore, by this definition most keratotic lesion cannot be CIS because keratosis shows maturation of the squamous epithelium. Therefore, the use of the specific term CIS in keratinizing dysplasias of the UADT has been questioned and is likely inappropriate in this setting; a more appropriate designation is keratinizing severe dysplasia.

Several points should be stressed relative to keratinizing dysplasia of the UADT:

- Invasive carcinoma develops from dysplasia limited in extent including only to the lower third (basal zone region) of the surface epithelium in the absence of full thickness dysplasia (ie, “classic” carcinoma in situ).
- Keratinizing severe dysplasia is often multifocal and frequently occurs adjacent to or near synchronous foci of invasive carcinoma.
- Keratinizing severe dysplasia has a rate of progression to invasive carcinoma that is greater than that of “classic” carcinoma in situ.
- A diagnosis of severe dysplasia requires therapeutic intervention, as well as clinical evaluation of the entire upper aerodigestive tract to exclude the possible presence of additional foci of dysplasia or carcinoma that may exist from field effect.

The end point for the grading of dysplasia is to convey to the clinician what is the potential biologic behavior of a given epithelial lesion. Keratotic epithelium without dysplasia carries a very low risk of developing subsequent carcinoma with reported incidences of 4% to 5%.<sup>19</sup> In contrast, keratotic epithelium with dysplasia is associated with an increased risk for the subsequent progression or development of premalignant or overtly carcinomatous changes varying from 16% to 19% of cases.<sup>19</sup> This risk of malignant transformation represents an increase of from 3 to 5 times as compared to carcinoma arising in keratotic lesions without atypia.<sup>19</sup> The risk for progression to invasive carcinoma in lesions diagnosed as keratosis with dysplasia varies depending on the degree of atypia/dysplasia<sup>19</sup>:

- for mild dysplasia – approximately 6%
- for moderate dysplasia – approximately 20%
- for severe dysplasia – approximately 24%

Given the absence of statistical significance in progression to invasive carcinoma between keratinizing moderate dysplasia and severe dysplasia, there may be merits in employing the 2-grade system currently in use for uterine cervical dysplasias (Bethesda classification) for keratinizing dysplasias of the UADT to include:

- Low-grade squamous intraepithelial lesion/neoplasia for mild dysplasia
- High-grade squamous intraepithelial lesion/neoplasia for moderate and severe dysplasias

Such a grading scheme for upper aerodigestive tract keratinizing dysplasias is not currently established or universally accepted.

## **N. Ancillary Testing**

There is increasing evidence that human papillomavirus (HPV) plays a pathogenic role in a subset of head and neck cancers, termed HPV-associated head and neck squamous cell carcinoma (HPV-HNSCC).<sup>37</sup> HPV, in particular the high risk type 16 (HPV-16), is present in most oropharyngeal carcinomas.<sup>38</sup> These carcinomas arise predominantly from the palatine tonsil and lingual tonsils of the oropharynx (ie, tonsil or base of tongue) and are nonkeratinizing carcinomas characterized by a basaloid cell type.<sup>39</sup> The International Agency for Research of Cancer (IARC) recently concluded that there is sufficient evidence that HPV-16 is causal for a subset of oropharyngeal cancers.<sup>40</sup> A similar association has been suggested but not confirmed for oral cavity carcinoma.<sup>40</sup> To date, there are no data linking HPV with laryngeal carcinoma, and the utility of testing for the presence of HPV in laryngeal carcinomas is unproven.



**References**

1. Patel S, Shah JP. Part II, head and neck sites. In: Edge SB, Byrd DR, Carducci MA, Compton CA, eds. *AJCC Cancer Staging Manual*. 7th ed. New York, NY: Springer; 2009.
2. Barnes L, Tse LLY, Hunt JL, et al. Tumours of the hypopharynx, larynx and trachea. In: Barnes L, Eveson JW, Reichart P et al, eds. *World Health Organization Classification of Tumours: Pathology and Genetics of Head and Neck Tumours*. Lyon, France: IARC Press; 2005.
3. Barnes L, Eveson JW, Reichart P, et al, eds. *World Health Organization Classification of Tumours: Pathology and Genetics of Head and Neck Tumours*. Lyon, France: IARC Press; 2005.
4. Barnes L. Neuroendocrine tumours. In: Barnes L, Eveson JW, Reichart P et al, eds. *World Health Organization Classification of Tumours: Pathology and Genetics of Head and Neck Tumours*. Lyon, France: IARC Press; 2005.
5. Crissman JD, Sakr WA. Squamous neoplasia of the upper aerodigestive tract. Intraepithelial and invasive squamous cell carcinoma. In: Pilch BZ, ed. *Head and Neck Surgical Pathology*. Philadelphia, PA: Lippincott Williams & Wilkins; 2001.
6. Mills SE, Gaffey MJ, Frierson HF, Jr. Tumors of the upper aerodigestive tract and ear. In: *Atlas of Tumor Pathology*. 3rd Series. Fascicle 26. Washington, DC: Armed Forces Institute of Pathology; 2000.
7. Ellis GL, Auclair PL. Salivary gland tumors: general considerations. In: Silverberg SG, ed. *Tumors of the Salivary Glands. Atlas of Tumor Pathology*. Series 4. Fascicle 9. Washington, DC: Armed Forces Institute of Pathology. Washington, DC. 2008.
8. Spiro RH, Huvos AG, Strong EW. Adenocarcinoma of salivary gland origin: clinicopathologic study of 204 patients. *Am J Surg*. 1982;144:423-431.
9. Szanto PA, Luna MA, Tortoledo ME, White RA. Histologic grading of adenoid cystic carcinoma of the salivary glands. *Cancer*. 1984;84:1062-1069.
10. Spiro RH, Thaler HT, Hicks WF, Kher UA, Huvos AG, Strong EW. The importance of clinical staging in minor salivary gland carcinoma. *Am J Surg*. 1991;162:330-336.
11. Kane WJ, McCaffrey TV, Olsen KD, Lewis JE. Primary parotid malignancies. A clinical and pathologic review. *Arch Otolaryngol Head Neck Surg*. 1991;117:307-315.
12. Greiner TC, Robinson RA, Maves MD. Adenoid cystic carcinoma: a clinicopathologic study with flow cytometric analysis. *Am J Clin Pathol*. 1989;92:711-720.
13. Auclair PL, Goode RK, Ellis GL. Mucoepidermoid carcinoma of intraoral salivary glands. Evaluation and application of grading criteria in 143 cases. *Cancer*. 1992;69:2021-30.
14. Goode RK, Auclair PL, Ellis GL. Mucoepidermoid carcinoma of the major salivary glands: clinical and histopathologic analysis of 234 cases with evaluation of grading criteria. *Cancer*. 1998;82:1217-24.
15. Brandwein MS, Ivanov K, Wallace DI, et al. Mucoepidermoid carcinoma: a clinicopathologic study of 80 patients with special reference to histological grading. *Am J Surg Pathol*. 2001;25:835-45.
16. Bradley PJ et al. Status of primary tumour surgical margins in squamous head and neck cancer: prognostic implications. *Curr Opin Otolaryngol Head Neck Surg*. 2007;15:74-81.
17. Laramore GE, Scott CB, al-Sarraf M, et al. Adjuvant chemotherapy for resectable squamous cell carcinomas of the head and neck: report on Intergroup Study 0034. *Int J Radiat Oncol Biol Phys*. 1992;23:705-713.

18. Zelefsky MJ, Harrison LB, Fass DE, Armstrong JG, Shah JP, Strong EW. Postoperative radiation therapy for squamous cell carcinomas of the oral cavity and oropharynx: impact of therapy on patients with positive surgical margins. *Int J Radiat Oncol Biol Phys*. 1993;25:17-21.
19. Barnes L. Diseases of the larynx, hypopharynx and trachea. In: Barnes L, ed. *Surgical Pathology of the Head and Neck*. 3<sup>rd</sup> ed. New York, NY: Informa Healthcare; 2009.
20. Wenig BM. Epithelial precursor lesions. In: Wenig BM, ed. *Atlas of Head and Neck Pathology*. 2<sup>nd</sup> ed. Philadelphia, PA: WB Saunders-Elsevier; 2008.
21. Smith BD, Haffty BG. Prognostic factors in patients with head and neck cancer. In: Harrison LB, Sessions RB, Hong WK, eds. *Head and Neck Cancer: A Multidisciplinary Approach*. 3<sup>rd</sup> ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2009: 51-75.
22. Fagan JJ, Collins B, Barnes L, et al. Perineural invasion in squamous cell carcinoma of the head and neck. *Arch Otolaryngol Head Neck Surg*. 1998;124:637-640.
23. Cooper JS, Pajak TF, Forastiere AA, et al. Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. *N Engl J Med*. 2004;350:1937-1944.
24. Bernier J, Dumenige C, Ozsahin M, et al. Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. *N Engl J Med*. 2004;350:1945-1952.
25. Woolgar J, Triantafyllou A. Neck dissections: a practical guide for the reporting histopathologist. *Curr Diag Pathol*. 2007;13:499-511.
26. Leemans CR, Tiwari R, Nauta JJ, van der Waal I, Snow GB. Regional lymph node involvement and its significance in the development of distant metastases in head and neck carcinoma. *Cancer*. 1993;71:452-456.
27. Johnson JT, Barnes EL, Meyers EN, et al. The extracapsular spread of tumors in cervical node metastases. *Head Neck Surg*. 1981;107:725-729.
28. Woolgar JA, Rogers SN, Lowe D, Brown JS, Vaughn ED. Cervical lymph node metastasis in oral cancer: the importance of even microscopic extracapsular spread. *Oral Oncol*. 2003;39:130-137.
29. Sobin LH, Gospodarowicz MK, Wittekind CH, eds. *UICC TNM Classification of Malignant Tumors*. 7<sup>th</sup> ed. New York, NY: Wiley-Liss; in press.
30. Robbins KT et al. Neck dissection classification update. *Arch Otolaryngol Head Neck Surg*. 2002;128:751-758.
31. Robbins TK et al. Consensus statement on the classification and terminology of neck dissection. *Arch Otolaryngol Head Neck Surg*. 2008;134:536-538.
32. Robbins T, Medina JE, Wolfe GT, Levine PA, Sessions RB, Pruet CW. Standardizing neck dissection terminology: official report of the academy's committee for head and neck surgery and oncology. *Arch Otolaryngol Head Neck Surg*. 1991;117:601-605.
33. Wittekind C, Greene FL, Henson DE, Hutter RVP, Sobin LH, eds. *TNM Supplement: A Commentary on Uniform Use*. 3<sup>rd</sup> ed. New York, NY: Wiley-Liss; 2003.
34. Singletary SE, Greene FL, Sobin LH. Classification of isolated tumor cells: clarification of the 6<sup>th</sup> edition of the American Joint Committee on Cancer Staging Manual. *Cancer*. 2003;90(12):2740-2741.
35. Flint PW, et al, eds. *Cummings Otolaryngology: Head and Neck Surgery*. 4<sup>th</sup> ed. Philadelphia, PA: Saunders; 2010.
36. Gale N, Pilch BZ, Sidransky D, Westra WH, Califano J. Epithelial precursor lesions. In: Barnes L, Eveson JW, Reichart P et al, eds. *World Health Organization*

- Classification of Tumours: Pathology and Genetics of Head and Neck Tumours.* Lyon, France: IARC Press; 2005.
37. Gillison ML. Human Papillomavirus and Prevention and Therapy of Head and Neck Cancer. In: Harrison LB, Sessions RB, Waun KH, eds. *Head and Neck Cancer: A Multidisciplinary Approach*. 3rd ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2009.
  38. Kreimer AR, Clifford GM, Boyle P, et al. Human papillomavirus types in head and neck squamous cell carcinomas worldwide: a systematic review. *Cancer Epidemiol Biomarkers Prev*. 2005;14:467-475.
  39. Gillison ML, Koch WM, Capone RB, et al. Evidence for a causal association between human papillomavirus and a subset of head and neck cancers. *J Natl Cancer Inst*. 2000;92:709-720.
  40. IACR Monographs on the Evaluation of Carcinogenic Risks to Humans. *Human Papillomavirus: IACR Monographs Volume 90*. Geneva, Switzerland: WHO Press; 2007: 1-636.